Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Koen Van Besien

TitlePROFESSOR
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ. Impact of a Multiplexed PCR Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019 Nov 05. PMID: 31687767.
      View in: PubMed
    2. Choe HK, van Besien K. Donor graft genotypes versus leukemia. Leuk Lymphoma. 2019 Jul; 60(7):1606-1607. PMID: 31238818.
      View in: PubMed
    3. van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 Jun 25; 3(12):1858-1867. PMID: 31217161.
      View in: PubMed
    4. Gergis U, van Besien K. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 Sep; 60(9):2101-2103. PMID: 31238760.
      View in: PubMed
    5. Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019 Dec; 54(12):2027-2038. PMID: 31190006.
      View in: PubMed
    6. Allan JN, Van Besien K. It's not all about the CNS. High dose methotrexate in DLBCL. Leuk Lymphoma. 2019 Aug; 60(8):1845-1847. PMID: 31120336.
      View in: PubMed
    7. Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 Jul; 60(7):1626-1631. PMID: 30997845.
      View in: PubMed
    8. Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 Jul; 60(7):1693-1696. PMID: 30741059.
      View in: PubMed
    9. Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H. The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 Aug; 60(8):2091-2093. PMID: 30698071.
      View in: PubMed
    10. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841.
      View in: PubMed
    11. Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG, Jenkins SG, Walsh TJ, Kreiswirth BN. Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018 11 13; 67(11):1720-1728. PMID: 29701766.
      View in: PubMed
    12. Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, Albano MS, Dobrila L, Scaradavou A, van Besien K. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biol Blood Marrow Transplant. 2019 03; 25(3):466-473. PMID: 30414955.
      View in: PubMed
    13. Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 Jul; 54(7):1058-1066. PMID: 30385869.
      View in: PubMed
    14. Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P, van Besien K, Mayer S. Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biol Blood Marrow Transplant. 2019 02; 25(2):e60-e64. PMID: 30661542.
      View in: PubMed
    15. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 09; 103(9):1577. PMID: 30171018.
      View in: PubMed
    16. Chaekal OK, van Besien K. A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5. PMID: 29966478.
      View in: PubMed
    17. Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van Besien K. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018 12; 59(12):2829-2835. PMID: 29790808.
      View in: PubMed
    18. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777. PMID: 29419425.
      View in: PubMed
    19. Sfeir MM, Schuetz A, Van Besien K, Borczuk AC, Soave R, Jenkins SG, Walsh TJ, Small CB. Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. J Clin Pathol. 2018 Jul; 71(7):626-630. PMID: 29367301.
      View in: PubMed
    20. Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456. PMID: 29330398.
      View in: PubMed
    21. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      View in: PubMed
    22. Reich-Slotky R, Cushing MM, Hsu YS, Ancharski M, Rojas JM, Scrimenti LM, Robilio S, Assalone D, Roselli T, Guarneri D, Vasovic LV, Goel R, Shore T, van Besien K. Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience. Transfusion. 2018 02; 58(2):339-344. PMID: 29193156.
      View in: PubMed
    23. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365. PMID: 29128555.
      View in: PubMed
    24. Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biol Blood Marrow Transplant. 2018 02; 24(2):288-293. PMID: 29061534.
      View in: PubMed
    25. Liu C, Frank DN, Horch M, Chau S, Ir D, Horch EA, Tretina K, van Besien K, Lozupone CA, Nguyen VH. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplant. 2017 Dec; 52(12):1643-1650. PMID: 28967895.
      View in: PubMed
    26. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442. PMID: 28826616.
      View in: PubMed
    27. Choe HK, van Besien K. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma. 2018 02; 59(2):272-273. PMID: 28812411.
      View in: PubMed
    28. Choe HK, van Besien K. Against the odds: haplo-cord grafts protect from GvHD and relapse. Bone Marrow Transplant. 2017 12; 52(12):1590-1591. PMID: 28628090.
      View in: PubMed
    29. Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258. PMID: 28573908.
      View in: PubMed
    30. Kanaan SB, Gammill HS, Harrington WE, De Rosa SC, Stevenson PA, Forsyth AM, Allen J, Cousin E, van Besien K, Delaney CS, Nelson JL. Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. Oncoimmunology. 2017; 6(5):e1311436. PMID: 28638735.
      View in: PubMed
    31. Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937. PMID: 28285081.
      View in: PubMed
    32. Choe HK, Gergis U, Mayer SA, Nagar H, Phillips AA, Shore TB, Smith MJ, van Besien K. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38. PMID: 27764032.
      View in: PubMed
    33. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601.
      View in: PubMed
    34. Mayer S, van Besien K. Second allogeneic transplantation: ever? never? or sometimes. Leuk Lymphoma. 2017 06; 58(6):1279-1280. PMID: 27842447.
      View in: PubMed
    35. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017 06; 58(6):1512-1514. PMID: 27786572.
      View in: PubMed
    36. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103. PMID: 27497531.
      View in: PubMed
    37. van Besien K, Childs R. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266. PMID: 27788764.
      View in: PubMed
    38. Dierickx D, Sprangers B, Van Besien K. HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leuk Lymphoma. 2016 10; 57(10):2241-2. PMID: 27379564.
      View in: PubMed
    39. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2017 02; 58(2):288-297. PMID: 27333804.
      View in: PubMed
    40. Thomas CM, Ippoliti C, Roboz GJ, Feldman E, Savva D, James S, van Besien K. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017 01; 58(1):230-232. PMID: 27240704.
      View in: PubMed
    41. Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang HL, Maiers M, Spellman S, van Besien K, Lee SJ, Karrison T, Artz A. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349. PMID: 27214075.
      View in: PubMed
    42. Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, Perales MA, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M. Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clin Infect Dis. 2016 08 15; 63(4):565-8. PMID: 27199460.
      View in: PubMed
    43. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356. PMID: 27131865.
      View in: PubMed
    44. Cirrone F, Ippoliti C, Wang H, Zhou XK, Gergis U, Mayer S, Shore T, van Besien K. Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leuk Lymphoma. 2016 11; 57(11):2555-9. PMID: 26984480.
      View in: PubMed
    45. Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May; 22(5):965-70. PMID: 26904972.
      View in: PubMed
    46. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055.
      View in: PubMed
    47. Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303. PMID: 27025789.
      View in: PubMed
    48. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630.
      View in: PubMed
    49. Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8. PMID: 26661996.
      View in: PubMed
    50. Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61. PMID: 26524732.
      View in: PubMed
    51. van Besien K. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036. PMID: 26463649.
      View in: PubMed
    52. Jacobs SE, Lamson DM, Soave R, Guzman BH, Shore TB, Ritchie EK, Zappetti D, Satlin MJ, Leonard JP, van Besien K, Schuetz AN, Jenkins SG, George KS, Walsh TJ. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. J Clin Virol. 2015 Oct; 71:51-8. PMID: 26370315.
      View in: PubMed
    53. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34. PMID: 26052909.
      View in: PubMed
    54. Storch E, Mark T, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Aug; 55(8):2010-6. PMID: 25808119.
      View in: PubMed
    55. Lindemans CA, van Besien K. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015 Jun; 17(6):723-729. PMID: 25791069.
      View in: PubMed
    56. Phillips AA, van Besien K. A new "age" for high dose therapy and autologous stem cell transplant. Leuk Lymphoma. 2015; 56(8):2233-4. PMID: 25641430.
      View in: PubMed
    57. Liu H, van Besien K. Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7. PMID: 25667129.
      View in: PubMed
    58. Segovia J, van Besien K. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2. PMID: 25495172.
      View in: PubMed
    59. Reich-Slotky R, Bachegowda LS, Ancharski M, Mendeleyeva L, Rubinstein P, Rennert H, Shore T, van Besien K, Cushing M. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion. 2015 Jun; 55(6):1147-53. PMID: 25652820.
      View in: PubMed
    60. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8. PMID: 25528388.
      View in: PubMed
    61. Preeshagul IR, Van Besien K, Mark TM. Controversies in multiple myeloma: to transplant or not? Curr Hematol Malig Rep. 2014 Dec; 9(4):360-7. PMID: 25145553.
      View in: PubMed
    62. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73. PMID: 25654478.
      View in: PubMed
    63. van Besien K. Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5-7 June 2014. Leuk Lymphoma. 2015 Apr; 56(4):877-81. PMID: 25058374.
      View in: PubMed
    64. Polliack A, Seymour J, Van Besien K, Treadway A. Statement of Retraction: Huang H, Wu D, Fu J, Chen G. "multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid". Leuk Lymphoma. 2014 Jun; 55(6):1437. PMID: 24850142.
      View in: PubMed
    65. van Besien K, Furman RR. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014 Jun; 55(6):1221-2. PMID: 24745938.
      View in: PubMed
    66. Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. PMID: 24564572.
      View in: PubMed
    67. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237.
      View in: PubMed
    68. van Besien K. Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013. Leuk Lymphoma. 2014 Aug; 55(8):1735-8. PMID: 24180330.
      View in: PubMed
    69. Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, Walsh TJ. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014 Dec; 55(12):2858-65. PMID: 24559288.
      View in: PubMed
    70. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8. PMID: 24641829.
      View in: PubMed
    71. Kosuri S, van Besien K. Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7. PMID: 24471910.
      View in: PubMed
    72. Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 May; 49(5):722-4. PMID: 24535131.
      View in: PubMed
    73. Eikmans M, van Halteren AG, van Besien K, van Rood JJ, Drabbels JJ, Claas FH. Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism. 2014; 5(2):24-39. PMID: 24762743.
      View in: PubMed
    74. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97. PMID: 24161923.
      View in: PubMed
    75. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70. PMID: 24065243.
      View in: PubMed
    76. Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, van Besien KM, Gordon LI, Smith SM. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013 Oct; 163(1):55-61. PMID: 23927371.
      View in: PubMed
    77. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3100-9. PMID: 23897963.
      View in: PubMed
    78. Polliack A, Van Besien K, Seymour J, Treadway A. Statement of retraction. Avilés A, Fernándezb R, Pérez F, Nambo MJ, Neri N, Talavera A, Castañeda C,González M, Cleto. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. 2013 Jul; 54(7):1571. PMID: 23777388.
      View in: PubMed
    79. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005.
      View in: PubMed
    80. Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5. PMID: 23648237.
      View in: PubMed
    81. Lin RJ, Larson RA, van Besien K, Rich ES. Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Rep Hematol. 2013; 2013:140138. PMID: 23607004.
      View in: PubMed
    82. van Besien K, Liu HT, Artz A. Microchimerism and allogeneic transplantation: we need the proof in the pudding. Chimerism. 2013 Jul-Sep; 4(3):109-10. PMID: 23511912.
      View in: PubMed
    83. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      View in: PubMed
    84. Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7. PMID: 23454184.
      View in: PubMed
    85. van Besien K, Shore T, Cushing M. Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013 01 17; 368(3):287-8. PMID: 23323912.
      View in: PubMed
    86. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9. PMID: 23310949.
      View in: PubMed
    87. Artz AS, van Besien K. Pre-transplant serum ferritin is prognostic but is it useful? Leuk Lymphoma. 2013 Jun; 54(6):1133-4. PMID: 23216268.
      View in: PubMed
    88. van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013; 2013:56-62. PMID: 24319163.
      View in: PubMed
    89. Churpek JE, Nickels E, Marquez R, Rojek K, Liu B, Lorenz R, Lepore J, Madzo J, Wickrema A, Artz AS, van Besien K, Godley LA. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9. PMID: 23258901.
      View in: PubMed
    90. Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, Pape L, Extermann M, Van Besien K, Artz AS. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013 Mar; 19(3):429-34. PMID: 23160006.
      View in: PubMed
    91. Geslain R, Uddin S, Liu H, Jiang H, van Besien K, Pan T, Wickrema A. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35. PMID: 23148990.
      View in: PubMed
    92. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91. PMID: 23142329.
      View in: PubMed
    93. van Besien K. cGVHD of skin: simple tools, great advances. Blood. 2012 Sep 27; 120(13):2537-8. PMID: 23019199.
      View in: PubMed
    94. Morawa E, Martin P, Gergis U, van Besien K, Shore T. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013 Apr; 54(4):885-8. PMID: 22897727.
      View in: PubMed
    95. Dierickx D, van Besien K. Therapeutic drug monitoring: a way to improve long-term immunological balance? Leuk Lymphoma. 2013 Jan; 54(1):5-6. PMID: 22857003.
      View in: PubMed
    96. Villa CH, Shore T, Van Besien K, Cushing M. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1867-75. PMID: 22796644.
      View in: PubMed
    97. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. PMID: 22571201.
      View in: PubMed
    98. Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. PMID: 22548695.
      View in: PubMed
    99. Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8. PMID: 22465977.
      View in: PubMed
    100. Pai RK, van Besien K, Hart J, Artz AS, O'Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7. PMID: 22280517.
      View in: PubMed
    101. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      View in: PubMed
    102. Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1255-64. PMID: 22198543.
      View in: PubMed
    103. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470.
      View in: PubMed
    104. van Besien K. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011 Nov; 23(6):681-91. PMID: 21946246.
      View in: PubMed
    105. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. PMID: 21976674.
      View in: PubMed
    106. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi. PMID: 22054733.
      View in: PubMed
    107. Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80. PMID: 21864038.
      View in: PubMed
    108. van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz AS. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9. PMID: 21749304.
      View in: PubMed
    109. van Besien K. Stem cell transplantation for indolent lymphoma: a reappraisal. Blood Rev. 2011 Sep; 25(5):223-8. PMID: 21641099.
      View in: PubMed
    110. Ramsdale E, Van Besien K. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leuk Lymphoma. 2011 Aug; 52(8):1415-7. PMID: 21599586.
      View in: PubMed
    111. Poiré X, van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111. PMID: 21702703.
      View in: PubMed
    112. Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1775-82. PMID: 21621629.
      View in: PubMed
    113. Ramsdale E, van Besien K, Smith SM. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011 Apr; 38(2):225-35. PMID: 21421112.
      View in: PubMed
    114. van Besien K. Cord blood transplant: the glass is half full--can we do better? Leuk Lymphoma. 2011 Apr; 52(4):554-5. PMID: 21438826.
      View in: PubMed
    115. Marino SR, Lin S, Maiers M, Haagenson M, Spellman S, Klein JP, Binkowski TA, Lee SJ, van Besien K. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Feb; 47(2):217-26. PMID: 21441965.
      View in: PubMed
    116. van Besien K, Kenkre V, Artz AS. T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter? J Clin Oncol. 2011 Mar 20; 29(9):e243; author reply e244. PMID: 21343548.
      View in: PubMed
    117. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. PMID: 21224011.
      View in: PubMed
    118. Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22. PMID: 21142785.
      View in: PubMed
    119. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852.
      View in: PubMed
    120. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6. PMID: 20837940.
      View in: PubMed
    121. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. PMID: 20699125.
      View in: PubMed
    122. Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50. PMID: 20496994.
      View in: PubMed
    123. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32. PMID: 20601033.
      View in: PubMed
    124. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006. PMID: 20536346.
      View in: PubMed
    125. Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010 Apr 14; 303(14):1421-2. PMID: 20388899.
      View in: PubMed
    126. Dew A, van Besien K. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956. PMID: 20220194.
      View in: PubMed
    127. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8. PMID: 20208570.
      View in: PubMed
    128. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. PMID: 20202482.
      View in: PubMed
    129. Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68. PMID: 20114084.
      View in: PubMed
    130. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46. PMID: 20085936.
      View in: PubMed
    131. Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun; 45(6):1068-76. PMID: 19915634.
      View in: PubMed
    132. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64. PMID: 19822306.
      View in: PubMed
    133. van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. PMID: 19821799.
      View in: PubMed
    134. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45. PMID: 20053330.
      View in: PubMed
    135. Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, Van Besien K, Artz A. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1394-9. PMID: 19822298.
      View in: PubMed
    136. Sharma M, Moore J, Nguyen V, Van Besien K. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009 Sep; 84(9):614-6. PMID: 19676117.
      View in: PubMed
    137. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1412-21. PMID: 19603345.
      View in: PubMed
    138. Loberiza FR, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9. PMID: 19589479.
      View in: PubMed
    139. O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1. PMID: 19660716.
      View in: PubMed
    140. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7. PMID: 19361753.
      View in: PubMed
    141. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63. PMID: 19361747.
      View in: PubMed
    142. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82. PMID: 19270260.
      View in: PubMed
    143. Poiré X, van Besien K. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol. 2009 Feb; 2(1):31-6. PMID: 21082992.
      View in: PubMed
    144. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17. PMID: 19135949.
      View in: PubMed
    145. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8. PMID: 20008246.
      View in: PubMed
    146. Foss F, van Besien K. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res. 2009; 144:209-32. PMID: 19779868.
      View in: PubMed
    147. Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91. PMID: 19142796.
      View in: PubMed
    148. Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec; 14(12):1323-33. PMID: 19041053.
      View in: PubMed
    149. Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. PMID: 18940674.
      View in: PubMed
    150. Calderwood MS, Mauer A, Tolentino J, Flores E, van Besien K, Pursell K, Weber SG. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol. 2008 Nov; 29(11):1019-25. PMID: 18823273.
      View in: PubMed
    151. van Besien K, Hari P. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15; 112(6):2585-6; author reply 2586-7. PMID: 18779408.
      View in: PubMed
    152. Nguyen V, van Besien K. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2. PMID: 18798096.
      View in: PubMed
    153. van Besien KW. Superiority of reduced-intensity conditioning for Hodgkin's lymphoma. J Clin Oncol. 2008 Aug 20; 26(24):4045-6; author reply 4046-7. PMID: 18711200.
      View in: PubMed
    154. Dew A, Collins D, Artz A, Rich E, Stock W, Swanson K, van Besien K. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41. PMID: 18640578.
      View in: PubMed
    155. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12. PMID: 18640574.
      View in: PubMed
    156. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74. PMID: 18621929.
      View in: PubMed
    157. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008 Jun; 14(6):719-23. PMID: 18489998.
      View in: PubMed
    158. O'Donnell PH, Artz AS, Undevia SD, Hart J, van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). J Clin Oncol. 2008 May 20; 26(15_suppl):7042. PMID: 27949605.
      View in: PubMed
    159. Smith SM, Pro B, Cisneros A, Smith S, Stiff P, Lester E, Modi S, Dancey JE, Vokes EE, van Besien K. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol. 2008 May 20; 26(15_suppl):8514. PMID: 27950972.
      View in: PubMed
    160. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      View in: PubMed
    161. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb; 14(2):236-45. PMID: 18215784.
      View in: PubMed
    162. Kang JA, Zhou Y, Weis TL, Liu H, Ulaszek J, Satgurunathan N, Zhou L, van Besien K, Crispino J, Verma A, Low PS, Wickrema A. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem. 2008 Mar 14; 283(11):6997-7006. PMID: 18174176.
      View in: PubMed
    163. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:52-8. PMID: 18821433.
      View in: PubMed
    164. Kline J, Subbiah S, Lazarus HM, van Besien K. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13. PMID: 18026144.
      View in: PubMed
    165. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32. PMID: 17846595.
      View in: PubMed
    166. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805. PMID: 17786717.
      View in: PubMed
    167. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181. PMID: 17502895.
      View in: PubMed
    168. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9. PMID: 17426059.
      View in: PubMed
    169. Samara MA, Brennan JM, Van Besien K, Larson RA. Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32. PMID: 17454648.
      View in: PubMed
    170. Gordon MK, Kraus M, van Besien K. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma. 2007 Apr; 48(4):816-8. PMID: 17454644.
      View in: PubMed
    171. van Besien K, Schouten H. Follicular lymphoma: a historical overview. Leuk Lymphoma. 2007 Feb; 48(2):232-43. PMID: 17325883.
      View in: PubMed
    172. Margolin KA, van Besien K, Peace DJ. An introduction to foundation and industry-sponsored research: practical and ethical considerations. Hematology Am Soc Hematol Educ Program. 2007; 498-503. PMID: 18024671.
      View in: PubMed
    173. Kline J, van Besien K, Nathanson J, Noffsinger A, Artz A. Severe intestinal graft-versus-host disease following autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):391-2. PMID: 16915228.
      View in: PubMed
    174. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      View in: PubMed
    175. van Besien K. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma. 2006 Aug; 47(8):1447-8. PMID: 16966249.
      View in: PubMed
    176. van Besien K. Standardizing chronic graft-versus-host disease. Future Oncol. 2006 Aug; 2(4):459-62. PMID: 16922612.
      View in: PubMed
    177. Danaher EH, Ferrans C, Verlen E, Ravandi F, van Besien K, Gelms J, Dieterle N. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24. PMID: 16676017.
      View in: PubMed
    178. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, Rizzo JD. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541-51. PMID: 16635789.
      View in: PubMed
    179. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006 May; 7(5):436-8. PMID: 16648049.
      View in: PubMed
    180. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006 Sep; 20(5):235-44. PMID: 16513231.
      View in: PubMed
    181. Artz AS, Kocherginsky M, Van Besien K. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2006 Mar; 132(6):747-54. PMID: 16487176.
      View in: PubMed
    182. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10. PMID: 16400339.
      View in: PubMed
    183. Schwake CJ, Eapen M, Lee SJ, Freytes CO, Giralt SA, Navarro WH, Rizzo JD, van Besien K, Loberiza FR. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant. 2005 Dec; 11(12):988-98. PMID: 16338621.
      View in: PubMed
    184. van Besien K, Deeg HJ. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol. 2005 Aug; 32(4):414-21. PMID: 16202687.
      View in: PubMed
    185. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      View in: PubMed
    186. van Besien K, Smith S, Lazarus HM. Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant. Curr Treat Options Oncol. 2005 Jul; 6(4):279-87. PMID: 15967081.
      View in: PubMed
    187. Smith SM, Pro B, van Besien K, Conner K, Karrison T, Wong S, Stiff P, Vokes E. A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol. 2005 Jun; 23(16_suppl):6625. PMID: 27944284.
      View in: PubMed
    188. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70. PMID: 15806131.
      View in: PubMed
    189. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. PMID: 15735047.
      View in: PubMed
    190. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy PL. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005 Feb; 46(2):239-42. PMID: 15621807.
      View in: PubMed
    191. Van Besien K. Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci. 2005 Feb; 32(1):45-53. PMID: 15737873.
      View in: PubMed
    192. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60. PMID: 15543195.
      View in: PubMed
    193. van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3. PMID: 15526015.
      View in: PubMed
    194. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004 Dec; 34(11):929-38. PMID: 15489883.
      View in: PubMed
    195. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01; 104(12):3797-803. PMID: 15280203.
      View in: PubMed
    196. Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94. PMID: 15148492.
      View in: PubMed
    197. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      View in: PubMed
    198. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      View in: PubMed
    199. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 203-20. PMID: 15561684.
      View in: PubMed
    200. Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15; 21(20):3744-53. PMID: 12963703.
      View in: PubMed
    201. Baron BW, van Besien K, Hoffman PC, Kohn OF, Rossof AH, Baron JM. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion. 2003 Sep; 43(9):1317-21. PMID: 12919436.
      View in: PubMed
    202. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman J. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6. PMID: 12942092.
      View in: PubMed
    203. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9. PMID: 12893748.
      View in: PubMed
    204. van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13. PMID: 12815472.
      View in: PubMed
    205. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien K. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6. PMID: 12732890.
      View in: PubMed
    206. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7. PMID: 12599231.
      View in: PubMed
    207. Ravandi F, van Besien K. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia. 2003 Jan; 17(1):271-2. PMID: 12529694.
      View in: PubMed
    208. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82. PMID: 12456505.
      View in: PubMed
    209. G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002 Oct 04; 297(4):760-4. PMID: 12359217.
      View in: PubMed
    210. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002 Jun 15; 168(12):5984-8. PMID: 12055203.
      View in: PubMed
    211. Devine SM, Jahagirdar B, van Besien K. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood. 2002 Jun 01; 99(11):4251-2; author reply 4252. PMID: 12043699.
      View in: PubMed
    212. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, Maynard V, Jessop E, Peace D, Huml M, Thomason D, Chen YH, van Besien K. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8. PMID: 11877308.
      View in: PubMed
    213. Smith SM, Grinblatt D, van Besien K. Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40. PMID: 12194719.
      View in: PubMed
    214. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700. PMID: 11535499.
      View in: PubMed
    215. Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62. PMID: 11607768.
      View in: PubMed
    216. van Besien K, Koshy M, Anderson-Shaw L, Talishy N, Dorn L, Devine S, Yassine M, Kodish E. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001 Sep; 28(6):545-9. PMID: 11607766.
      View in: PubMed
    217. van Besien K, Keralavarma B, Devine S, Stock W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25. PMID: 11516091.
      View in: PubMed
    218. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
      View in: PubMed
    219. van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001 Mar 15; 19(6):1855-64. PMID: 11251018.
      View in: PubMed
    220. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404. PMID: 11313669.
      View in: PubMed
    221. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44. PMID: 11157013.
      View in: PubMed
    222. Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96. PMID: 11313668.
      View in: PubMed
    223. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15; 19(2):406-13. PMID: 11208832.
      View in: PubMed
    224. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8. PMID: 10967575.
      View in: PubMed
    225. van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman R. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9. PMID: 10982293.
      View in: PubMed
    226. van Besien K, Champlin IK, McCarthy P. Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol. 2000 Feb; 18(3):702-3. PMID: 10653889.
      View in: PubMed
    227. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7. PMID: 10816027.
      View in: PubMed
    228. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8. PMID: 10516680.
      View in: PubMed
    229. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      View in: PubMed
    230. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Körbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70. PMID: 10438735.
      View in: PubMed
    231. Warkentin D, Ippoliti C, Bruton J, Van Besien K, Champlin R. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul; 24(1):57-61. PMID: 10435736.
      View in: PubMed
    232. Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81. PMID: 10373061.
      View in: PubMed
    233. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      View in: PubMed
    234. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, van Besien K, Horowitz MM. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb; 17(2):534-45. PMID: 10080597.
      View in: PubMed
    235. Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 1999; 5(1):36-45. PMID: 10232739.
      View in: PubMed
    236. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6. PMID: 9716615.
      View in: PubMed
    237. Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93. PMID: 9508181.
      View in: PubMed
    238. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84. PMID: 9454747.
      View in: PubMed
    239. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9. PMID: 9440724.
      View in: PubMed
    240. van Besien K, Margolin K, Champlin R, Forman S. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S54-8. PMID: 9457395.
      View in: PubMed
    241. Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 1997 Sep; 20(6):491-5. PMID: 9313883.
      View in: PubMed
    242. van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6. PMID: 9310192.
      View in: PubMed
    243. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      View in: PubMed
    244. Gajewski J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Hunt L, Giralt S, Chan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin R. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82. PMID: 9267667.
      View in: PubMed
    245. van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997 Jun; 8(6):515-24. PMID: 9261519.
      View in: PubMed
    246. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73. PMID: 9163617.
      View in: PubMed
    247. van Besien K, Verschraegen C, Mehra R, Giralt S, Kudelka AP, Edwards CL, Piamsonboom S, Termrungruanglert W, Champlin R, Kavanagh JJ. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9. PMID: 9159354.
      View in: PubMed
    248. van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Rondón G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997 May; 19(10):977-82. PMID: 9169641.
      View in: PubMed
    249. Rondón G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma. 1997 May; 25(5-6):463-7. PMID: 9250816.
      View in: PubMed
    250. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4. PMID: 9130690.
      View in: PubMed
    251. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60. PMID: 9052911.
      View in: PubMed
    252. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73. PMID: 9053492.
      View in: PubMed
    253. Piamsomboon S, Kudelka AP, Termrungruanglert W, Van Besien K, Edwards CL, Lifshitz S, Schomer DF, Champlin R, Mante RP, Kavanagh JJ, Verschraegen CF. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol. 1997; 18(6):453-6. PMID: 9443008.
      View in: PubMed
    254. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7. PMID: 9116608.
      View in: PubMed
    255. Verschraegen CF, van Besien KW, Dignani C, Hester JP, Andersson BS, Anaissie E. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis. 1997; 29(4):436-8. PMID: 9360268.
      View in: PubMed
    256. Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10. PMID: 8990368.
      View in: PubMed
    257. van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin R. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42. PMID: 8918502.
      View in: PubMed
    258. Körbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90. PMID: 8932841.
      View in: PubMed
    259. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307. PMID: 8629675.
      View in: PubMed
    260. van Besien K, Giralt S. Autologous bone marrow transplantation for leukemia and lymphoma. Cancer Treat Res. 1996; 84:207-59. PMID: 8724632.
      View in: PubMed
    261. Giralt SA, van Besien K. Treatment of relapse after allogeneic bone marrow transplantation. Cancer Treat Res. 1996; 84:279-90. PMID: 8724634.
      View in: PubMed
    262. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43. PMID: 7492795.
      View in: PubMed
    263. Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B, et al. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology. 1995 Dec; 46(6):811-5. PMID: 7502421.
      View in: PubMed
    264. Körbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8. PMID: 7545476.
      View in: PubMed
    265. Giralt S, O'Brien S, Talpaz M, Van Besien K, Chan KW, Rondón G, Andersson B, Mehra R, Khouri I, Estey E, et al. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22. PMID: 9384668.
      View in: PubMed
    266. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102. PMID: 7738615.
      View in: PubMed
    267. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55. PMID: 7655380.
      View in: PubMed
    268. Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65. PMID: 7888684.
      View in: PubMed
    269. van Besien K, Demuynck H, Lemaistre CF, Bogaerts MA, Champlin R. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995 Feb; 15(2):321-3. PMID: 7773226.
      View in: PubMed
    270. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30. PMID: 8083714.
      View in: PubMed
    271. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr; 12(4):748-58. PMID: 8151318.
      View in: PubMed
    272. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994 Apr; 13(4):461-4. PMID: 8019472.
      View in: PubMed
    273. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8. PMID: 8104539.
      View in: PubMed
    274. Van Besien K, Tricot G, Hoffman R. Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes. Am J Hematol. 1992 May; 40(1):47-50. PMID: 1340759.
      View in: PubMed
    275. Straneva JE, van Besien KW, Derigs G, Hoffman R. Is interleukin 6 the physiological regulator of thrombopoiesis? Exp Hematol. 1992 Jan; 20(1):47-50. PMID: 1577093.
      View in: PubMed
    276. van Besien K, Tricot G, Golichowski A, Padilla L, Hoffman R. Pregnancy-associated aplastic anemia--report of 3 cases. Eur J Haematol. 1991 Oct; 47(4):253-6. PMID: 1954983.
      View in: PubMed
    277. van Besien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res. 1991 Apr; 62(1-2):23-9. PMID: 1712988.
      View in: PubMed
    278. Srour EF, Brandt JE, Briddell RA, Leemhuis T, van Besien K, Hoffman R. Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells. 1991; 17(2):287-95. PMID: 1717081.
      View in: PubMed
    279. Srivastava A, Bruno E, Briddell R, Cooper R, Srivastava C, van Besien K, Hoffman R. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood. 1990 Nov 15; 76(10):1997-2004. PMID: 2146978.
      View in: PubMed
    280. Dayton MA, van Besien K, Tricot G, Hoffman R. Preleukemic state preceding adult acute lymphoblastic leukemia. Am J Med. 1990 Nov; 89(5):657-62. PMID: 2239985.
      View in: PubMed
    281. Brandt J, Srour EF, van Besien K, Briddell RA, Hoffman R. Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. J Clin Invest. 1990 Sep; 86(3):932-41. PMID: 1697607.
      View in: PubMed
    282. van Besien K, Nichols CR, Tricot G, Langefeld C, Miller ME, Akard L, English DK, Graves VL, Cheerva A, McCarthy LJ, et al. Characteristics of engraftment after repeated autologous bone marrow transplantation. Exp Hematol. 1990 Aug; 18(7):785-8. PMID: 2165911.
      View in: PubMed
    283. Brandt JE, Srour EF, van Besien K, Hoffman R. Characterization of human hematopoietic stem cells. Prog Clin Biol Res. 1990; 352:29-36. PMID: 2205867.
      View in: PubMed
    284. Hoffman R, Briddell RA, van Besien K, Srour EF, Guscar T, Hudson NW, Ganser A. Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1989 Jul 13; 321(2):97-102. PMID: 2659998.
      View in: PubMed
    285. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul; 7(7):932-9. PMID: 2544687.
      View in: PubMed
    286. Van Hootegem P, Van Besien K, Broeckaert L, Rutgeerts P, Fevery J. Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival. J Clin Gastroenterol. 1988 Aug; 10(4):368-72. PMID: 3262137.
      View in: PubMed
    Van Besien's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _